title: NICE confirms advanced breast cancer drug is too expensive for NHS.
authors.affiliation: London.
authors.forename: Caroline
authors.initials: C
authors.lastname: White
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics*; D000970:Antineoplastic Agents / Q000191:economics*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003362:Cost-Benefit Analysis; D004739:England; D005260:Female; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000191:economics; D013222:State Medicine / Q000191:economics*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine